***Curriculum vitae***

|  |  |
| --- | --- |
| **Date Prepared:** | 6/17/2020 |
| **Name:** | Pier Paolo Scaglioni, MD |
| **Office Address:** | University of Cincinnati College of MedicineThe Vontz Center for Molecular Studies3125 Eden Avenue, Rm. 3118Cincinnati, OH  45219-2293 |
| **Work Phone:**  | (513) 558-2115 |
| **Work E-Mail:**  | Scaglipr@ucmail.uc.edu |
| **Work Fax:** | (513) 558-2125 |
| **Place of Birth:** | Mirandola, Italy |

**Education**

|  |  |  |  |
| --- | --- | --- | --- |
| Year | Degree(Honors) | Field of Study(Thesis advisor for PhDs) | Institution |
| 1989 | MD Degree, Magna cum Laude |  | University of Modena Medical School, Italy |

**Postdoctoral Training**

|  |  |  |  |
| --- | --- | --- | --- |
| Year(s) | Titles | Specialty/Discipline(Lab PI for postdoc research) | Institution |
| 1989-1994 | Resident | Internal Medicine | University of Modena Medical School, Italy. |
| 1994-1998 | Research fellow | Virology, Lab Director: Jack R. Wands, MD | Massachusetts General Hospital |
| 1998-2001 | Intern-Resident | Internal Medicine | Montefiore Medical Center, Bronx, NY |
| 2001-2005 | Fellow | Hematology/Oncology | Memorial Sloan Kettering Cancer Center, New York, NY |
| 2002-2005 | Research Fellow | Cancer Biology and Genetics, Lab Director: Pier Paolo Pandolfi, MD. Ph.D. | Memorial Sloan Kettering Cancer Center, New York, NY |

**Current Licensure and Certification**

Licensure

2001 New York State Medical License (presently not registered)

2007 Texas State Medical License (presently not registered)

2017 Ohio State Medical License

Board and Other Certification

2001 Board Certification Internal Medicine

2004 Board Certification Medical Oncology (currently certified)

**Honors and Awards**

|  |  |  |
| --- | --- | --- |
| Year | Name of Honor/Award | Awarding Organization |
| 1989 | Prize for Italian Researchers younger than 35 years of age | Medicina , Firenze |
| 1991 | Research Fellowship | Terme di Chianciano S.p.A. |
| 2001 | Citation in recognition as an outstanding House Officer | Montefiore Medical Center/A. Einstein College of Medicine |
| 2003 | Young Investigator Award | American Society of Clinical Oncology |
| 2003 | Oncology Fellows Award | Cancer and leukemia Group B |
| 2003 | Travel Award | American Society of Hematology |
| 2004 | Clinical Scholars Training Program in Biomedical Research  | Memorial Sloan-Kettering Cancer Center Post-doctoral fellowship |
| 2004 | Diner Award | Doris Duke Foundation |
| 2004 | Travel Award  | American Society of Hematology |
| 2008 | The Gibbie Award | The Ryan Gibson Foundation |
| 2012 | The Gibbie Award | The Ryan Gibson Foundation |
| 2013 | Friends’ Award in Cancer research | Friends of the Comprehensive Cancer Center |

**Professional Memberships**

1991 Member, American Association for the Advancement of Science

2010 Member, American Association for Cancer Research

**Faculty Academic Appointments**

|  |  |  |  |
| --- | --- | --- | --- |
| Year(s) | Academic Title | Department | Academic Institution |
| 2005-2006 | Instructor | Department of Medicine, Hematology Service | Memorial Sloan Kettering Cancer Center, New York, NY |
| 2006-2014 | Assistant Professor | Department of Medicine, Division of Hematology/Oncology  | UT Southwestern Medical Center, Dallas, TX |
|  |  |  |  |
| 2014-2018 | Associate Professor | Department of Medicine, Division of Hematology/Oncology | UT Southwestern Medical Center, Dallas, TX |
| 2018- | Professor and Director | Department of Medicine, Division of Hematology/Oncology | University of Cincinnati College of Medicine |

**Appointments at Hospitals/Affiliated Institutions**

|  |
| --- |
| Past |
| Year(s) | Position Title | Department/Division | Institution |
| 1998-2001 | Intern-Resident | Internal Medicine | Montefiore Medical Center, Bronx, NY |
| 2001-2005 | Fellow | Hematology/Oncology | Memorial Sloan Kettering Cancer Center, New York, NY |
| Current |
| Year(s) | Position Title | Department/Division | Institution |
| 2006-2014 | Assistant Professor | Department of Medicine, Division of Hematology/Oncology  | UT Southwestern Medical Center, Dallas, TX |
| 2012-2014 | Assistant Professor | Department of Medicine, Division of Hematology/Oncology | Parkland Memorial Hospital, Dallas, TX |
| 2014-2018 | Associate Professor | Department of Medicine, Division of Hematology/Oncology | UT Southwestern Medical Center, Dallas, TX |
| 2014-2018 | Associate Professor | Department of Medicine, Division of Hematology/Oncology | Parkland Memorial Hospital, Dallas, TX |
| 2018- | Professor | Department of Medicine, Division of Hematology/Oncology | University of Cincinnati Medical Center |
| 2018- | Professor | Department of Medicine, Division of Hematology/Oncology | UC Health West Chester Hospital |
| 2018 | Medical Director | Department of Medicine, Division of Hematology/Oncology | UC Health Barret Cancer Center |
| 2020 | Interim Director | Department of Medicine, Division of Hematology/Oncology | The George L. Strike Stem Cell Transplant and Pheresis Center at the University of Cincinnati |

**Major Administrative/Leadership Positions**

|  |  |  |
| --- | --- | --- |
| Year(s) | Position Title | Institution |
| 2015-2018 | Co-Leader Cancer Cell Networks | Simmons Cancer Center, UT Southwestern Medical Center  |
| 2016-2018 | Director, Cancer Center Grand Rounds | Simmons Cancer Center, UT Southwestern Medical Center |
| 2018 - | Medical Director | UC Health Barret Cancer Center |  |
| 2018 -  | Division Director, Division of Hematology/Oncology | University of Cincinnati College of Medicine |  |
| 2020 | Interim Director | The George L. Strike Stem Cell Transplant and Pheresis Center at the University of Cincinnati |  |

**Committee Service (***Member, unless noted otherwise)*

|  |  |  |
| --- | --- | --- |
| Year(s) | Name of Committee | Institution/Organization |
| UTSW |
| 2012-2017 | Student Award Committee | UT Southwestern Medical Center Graduate School of Biomedical Studies |
| 2015-2018  | Steering Committee, Cancer Biology Graduate Program  | UT Southwestern Medical Center Graduate School of Biomedical Studies |
| 2020 | Scientific Advisory CommitteeBasic Science Working Group  | University of Cincinnati Cancer Center |
| Hospital |
| NA |  |  |
|  |  |  |
| State/Regional |
| NA |  |  |
|  |  |  |
| National/International |
| NA |  |  |
|  |  |  |

**Professional Societies**

|  |  |
| --- | --- |
| Dates | Society Name, member of |
| 2008-2018 | Texas Medical Association |
| 2018- | Cincinnati Medical Society |
|  | Committees  |
|  |  |
|  | Fellowships |
|  |  |

**Grant Review Activities**

|  |  |  |
| --- | --- | --- |
| Year(s) | Name of Review Committee | Organization |
| 2010-2016 |  | National Research Council of Singapore |
| 2010-2013 |  | The Florida Biomedical Research Program |
| 2013 Ad Hoc | Toxicology, Pharmacology and Cellular Signaling | French National Institute of Health and Medical Research (INSERM). Unit S747, University PARIS DESCARTES |
| 2013-2015 | Basic Cancer Research Fellowship Scientific Review Committee | American Association for the Advancement of Cancer Research |
| 2014-2015 | J study section  | National Cancer Institute |
| 2014 Ad Hoc |  | Austrian Science Fund (Biological and Medical Sciences) |
| 2015-2018 | Oncology Fellowship F09A-D panel | National Cancer Institute |
| 2017-2018 | ZRG1 study section | National Cancer Institute |
| 2019 |  | Swiss Cancer League/Swiss Cancer Research |

**Editorial Activities**

|  |  |
| --- | --- |
| Year(s) | Journal Name |
| Editor/Associate Editor |
|  |  |
|  |  |
| Editorial Board |
|  | NA |
|  |  |
| Ad Hoc Reviewer (please note that the date indicates the initial review, in several cases I have reviewed several manuscripts over the years) |
| Since 2006 | Nature Cell Biology |
| Since 2006 | Oncogene |
| Since 2009 | Cancer Research |
| Since 2010 | PLos ONE |
| Since 2010 | Cancer research |
| Since 2011 | Cell Research |
| Since 2011 | Genes and Cancer |
| Since 2011 | Cancer letters |
| Since 2012 | The Journal of Clinical Investigation |
| Since 2012 | Molecular Cancer Therapeutics |
| Since 2012 | International Journal of Cancer |
| Since 2014 | Cancer Discovery |
| Since 2016 | Oncotarget |

**Grant Support**

|  |  |
| --- | --- |
| Past | *Grantor:* **5P50 CA70907-15 NIH/NCI** |
|  | University of Texas SPORE (Special Program of Research Excellence) in Lung Cancer |
|  | *Title of Project* *3*: Preclinical Development and Clinical Testing of MEK and PI3K Targeted Therapy for KRAS-mutant NSCLC as a Method of Radiosensitization and Metastasis Inhibition” |
|  | *Role (Principal Investigator, Co-Investigator):* Co-PI Project 3 |
|  | *Annual amount (direct costs only):* $ 46, 742 |
|  | *Total amount of award (if multi-year) and dates (direct costs only):* $ $241, 845Dates 9/21/2015-8/31/2019 |
|  |  |
|  | *Grantor:* **Cancer Prevention and Research Institute of Texas (CPRIT) Multi-Investigator Research Award RP150519**  |
|  | *Title of Project:* Defining and Defeating Mechanistic Subtypes of KRAS-mutant Lung Cancers. |
|  | *Role (Principal Investigator, Co-Investigator):* Co-PI |
|  | *Annual amount (direct costs only):* $ $ 220,000 |
|  | *Total amount of award (if multi-year) and dates (direct costs only):* $ 880,000Dates: 6/1/2016-5/31/2020 (transferred to Dr. John Minna at UT Southwestern medical Center) |
|  |  |
|  | *Grantor:* **American Cancer Society Scholar Award**  |
|  | *Title of Project:* Identification of critical components of the K-RAS network in lung cancer. |
|  | *Role (Principal Investigator, Co-Investigator):* PI |
|  | *Annual amount and date (direct costs only):* $ 150,000 |
|  | *Total amount of award (if multi-year) and dates (direct costs only):* $ 600,0001/2013-9/2018 |
|  |  |
|  | *Grantor:* Cancer Prevention and Research Institute of Texas RP140672 |
|  | *Title of Project:* Mutant KRAS reprograms lipid metabolism exposing b-oxidation as a novel therapeutic target in lung cancer |
|  | *Role:* PI |
|  | *Annual amount (direct costs only):* $ $ 227,395 |
|  | *Total amount of award (direct costs only):* $ 687,759 |
|  | *Dates:* 8/31/2014-8/30/2017 |
|  |  |
|  | *Grantor:* **Texas 4000** |
|  | *Title of Project:* Exploitation of Fatty Acid β-oxidation as a novel therapeutic target in lung cancer |
|  | *Role (Principal Investigator, Co-Investigator):* PI |
|  | *Annual amount and date (direct costs only):* $ 50,000 2015 |
|  | *Total amount of award (if multi-year) and dates (direct costs only) NA* |
|  | *One time gift* |
|  |  |
|  | *Grantor:* **Cancer Research Institute of Texas RP101251** |
|  | *Title of Project:* Development of Nuclear Receptor and Coregulator Profiles forDiagnostic and Therapeutic |
|  | *Role (Principal Investigator, Co-Investigator):* Collaborator |
|  | *Annual amount and date (direct costs only):* $100,000 |
|  | *Total amount of award (if multi-year) and dates (direct costs only):* $500,0009/2012-9/2018 |
|  |  |
|  | *Grantor:* **CDMRP LCRP Investigator-Initiated Research Award** |
|  | *Title of Project:* Deconstruction of oncogenic K-RAS signaling reveals focal adhesion kinase as a novel therapeutic target in NSCLC |
|  | *Role (Principal Investigator, Co-Investigator):* PI |
|  | *Annual amount and date (direct costs only):* $ 175,000 |
|  | *Total amount of award (if multi-year) and dates (direct costs only):* $ 525,0009/2012-9/2016 (NCE) |
|  |  |
|  | *Grantor:* **NIH/NCI RO1 CA 137195A1** |
|  | *Title of Project:* Characterization and Drug Targeting of the PML Tumor Suppressor in Lung Cancer.  |
|  | *Role:* PI |
|  | *Total amount (direct costs only):* $ 225,000 |
|  | *Dates:* 7/1/2009-6/30/2015 (NCE) |
|  |  |
|  | *Grantor:* **Texas 4000** |
|  | *Title of Project:* Exploitation of Fatty Acid β-oxidation as a novel therapeutic target in lung cancer |
|  | *Role (Principal Investigator, Co-Investigator):* PI |
|  | *Annual amount and date (direct costs only):* $ 30,000 2014 |
|  | *Total amount of award (if multi-year) and dates (direct costs only) NA* |
|  | *One time gift* |
|  | *Total amount of award (if multi-year) and dates (direct costs only):* $ 1,037,500 5/2009-5/2014 |
|  | *Annual amount and date (direct costs only):* $ 50,000 2013 |
|  | *Total amount of award (if multi-year) and dates (direct costs only) NA* |
|  | *Annual amount and date (direct costs only):* $ 50,000 2012 |
|  | *Total amount of award (if multi-year) and dates (direct costs only):* NA |
|  |  |
|  | *Grantor:* **The Ryan Gibson Foundation** |
|  | *Title of Project:* Role of the PIAS1 E3 SUMO ligase in APL |
|  | *Role (Principal Investigator, Co-Investigator):* PI |
|  | *Annual amount and date (direct costs only):* $ 50,000 2012 |
|  | *Total amount of award (if multi-year) and dates (direct costs only):* one time award |
|  |  |
|  | *Grantor:* **National Institute of Health K08 CA 112325** |
|  | *Title of Project:* Post-transcriptional regulation of PML function  |
|  | *Role (Principal Investigator, Co-Investigator):* PI |
|  | *Annual amount and date (direct costs only):* $ 105,000 |
|  | *Total amount of award (if multi-year) and dates (direct costs only):* $ 525,0008/01/05-7/30/10 |
|  |  |
|  | *Grantor:* **Concern Foundation Conquer Cancer Now** |
|  | *Title of Project:* Exploiting oncogene addiction in lung cancer therapy  |
|  | *Role (Principal Investigator, Co-Investigator):* PI |
|  | *Annual amount and date (direct costs only):* $ 50,000 |
|  | *Total amount of award (if multi-year) and dates (direct costs only):* $ 100,0007/08-6/10 |
|  |  |
|  | *Grantor:* **The Ryan Gibson Foundation** |
|  | *Title of Project:* Development of a novel targeted therapy for myeloid leukemias  |
|  | *Role (Principal Investigator, Co-Investigator):* PI |
|  | *Annual amount and date (direct costs only):* $ 50,000 2008 |
|  | *Total amount of award (if multi-year) and dates (direct costs only):* NA |
|  |  |
|  | *Grantor:* **American Cancer Society Institutional Research Grant** |
|  | *Title of Project:* Exploiting oncogene addiction and premature senescence for lung cancer therapy  |
|  | *Role (Principal Investigator, Co-Investigator):* PI |
|  | *Annual amount and date (direct costs only):* $ 50,000 2008 |
|  | *Total amount of award (if multi-year) and dates (direct costs only):* NA  |
|  |  |
|  | *Grantor:* **Steps for Breaths Lung Cancer Research Initiative** |
|  | *Title of Project:* Exploiting oncogene addiction and premature senescence for lung cancer therapy  |
|  | *Role (Principal Investigator, Co-Investigator):* PI |
|  | *Annual amount and date (direct costs only):* $ 50,000 |
|  | *Total amount of award (if multi-year) and dates (direct costs only):* $ 100,0009/2004-9/2006 |
|  |  |
|  | *Grantor:* **Memorial Sloan-Kettering Cancer Center** **Clinical Scholars Training Program in Biomedical Research Charles A. Dana Fellowship**  |
|  | *Title of Project:* Post-transcriptional regulation of PML tumor suppressive function |
|  | *Role (Principal Investigator, Co-Investigator):* Trainee |
|  | *Annual amount and date (direct costs only):* $ 30,000 |
|  | *Total amount of award (if multi-year) and dates (direct costs only):* $ 35,0007/2004-6/2005 |
|  |  |
|  | *Grantor:* **Memorial Sloan-Kettering Cancer Center** **Michael and Ethel L. Cohen Foundation Fellowship**  |
|  | *Title of Project:* Post-transcriptional regulation of PML tumor suppressive function |
|  | *Role (Principal Investigator, Co-Investigator):* Trainee |
|  | *Annual amount and date (direct costs only):* $ 20,000 |
|  | *Total amount of award (if multi-year) and dates (direct costs only):* $ 20,0007/2004-6/2005 |
|  |  |
|  | *Grantor:* **CALGB Oncology Fellows Award**  |
|  | *Title of Project:* Aberrant degradation of the romyeolocytic leukemia gene protein in oncogenesis: correlation with clinical outcome and cell cycle control. |
|  | *Role (Principal Investigator, Co-Investigator):* Trainee |
|  | *Annual amount and date (direct costs only):* $ 20,000  |
|  | *Total amount of award (if multi-year) and dates (direct costs only):* $ 20,0007/01/03-6/30/04 |
|  |  |
|  | *Grantor:* **American Society of Clinical Oncology Young Investigator Award**  |
|  | *Title of Project:* Aberrant degradation of the romyeolocytic leukemia gene protein in oncogenesis: correlation with clinical outcome and cell cycle control. |
|  | *Role (Principal Investigator, Co-Investigator):* Trainee |
|  | *Annual amount and date (direct costs only):* $ 30,000  |
|  | *Total amount of award (if multi-year) and dates (direct costs only):* $ 30,0007/01/03-6/30/04 |
|  |  |
|  | *Grantor:* **National Institute of Health** **CA009207-26** **NCI T32 Institutional Training Grant** PI: Dr. George Bosl, Memorial Sloan-Kettering Cancer Center) |
|  | *Title of Project:* Aberrant degradation of the romyeolocytic leukemia gene protein in oncogenesis: correlation with clinical outcome and cell cycle control. |
|  | *Role (Principal Investigator, Co-Investigator):* Trainee |
|  | *Annual amount and date (direct costs only):* $ 35,000  |
|  | *Total amount of award (if multi-year) and dates (direct costs only):* $ 35,0007/2002-6/2003 |

**Clinical Trials Activities**

|  |  |
| --- | --- |
| Present | *Grantor:* **3V-Biosciences** |
| 2019 | *Title of Project:* A Phase 2 Single-Center Pharmacodynamic Study Of TVB-2640 In Kras Mutant Non-Small Cell Lung Carcinomas |
|  | *Role (Principal Investigator, Co-Investigator):* David Gerber and Pier Paolo Scaglioni |
|  |  |

|  |  |
| --- | --- |
| Past | *Grantor:* **Verastem, Inc.** |
| 2013 | *Title of Project: Title of Project:* Phase II Study of VS-6063 in Patients with KRAS Mutant Non-Small Cell Lung Cancer. ClinicalTrials.gov Identifier: NCT01951690 |
| NA | *Role (Principal Investigator, Co-Investigator):* David Gerber and Pier Paolo Scaglioni |
|  |  |

**Teaching Activities at UT Southwestern Medical Center**

|  |  |
| --- | --- |
| Year(s) | Activity |
| Medical and graduate school didactic and small group teaching |
| 2007 | Cancer Biology Graduate Program Lecture: Modeling lung cancer in the mouse |
| 2008 | MSTP lecture: modeling lung cancer in the mouse |
| 2008 | Cancer Biology Graduate Program Lecture: Mouse Models of Lung Cancer |
| 2009 | UTSW Graduate School of Biomedical StudiesGene threads discussion group (5 small group teaching sessions) |
| 2010 | Cancer Biology Graduate Program Lecture: Mouse Models of Lung Cancer |
| 2011 | Cancer Biology Graduate Program Lecture: Mouse Models of Lung Cancer |
| 2012 | Cancer Biology Graduate Program Lecture: Deconstruction of oncogenic networks in APL sets the stage for the development of novel targeted cancer therapies |
| 2013 | Cancer Biology Graduate Program Lecture: Deconstruction of oncogenic networks in APL sets the stage for the development of novel targeted cancer therapies |
| 2014 | Cancer Biology Graduate Program Lecture: Deconstruction of oncogenic networks in APL sets the stage for the development of novel targeted cancer therapies |
| 2015 | Cancer Biology Graduate Program Lecture: Deconstruction of oncogenic networks in APL sets the stage for the development of novel targeted cancer therapies |
| 2016 | Cancer Biology Graduate Program Lecture: Deconstruction of oncogenic networks in APL sets the stage for the development of novel targeted cancer therapies |
| 2017 | Cancer Biology Graduate Program Lecture: Deconstruction of oncogenic networks in APL sets the stage for the development of novel targeted cancer therapies |
|  |  |
| Dissertation committees |
|  | 2014 Krishna Luitel, Cancer Biology Program2014 William Peeples, Biochemistry2016 Wenting Du, Cancer Biology |
|  | ***Graduated students***2007-2010 James Sullivan, Cancer Biology Program 2007-2010 Hirotoshi Hoshiyama, Cancer Biology Program2008-2012 Shaina Porter, Cancer Biology Program2009-2012 Aric Whitington, Cancer Biology Program2009-2013 Demetra Farley, Cell Regulation Program2010-2013 Christopher Desevo, Cancer Biology Program2010-2013 Robert Borkowski, Cancer Biology Program 2010-2014 Alejandro D’Brot, Genetics and Development2010-2014 Aadil Kaisani, Cancer Biology Program 2011-2015 Patrick Dospoy, Cancer Biology Program 2012-2015 Zachary Moore, Cancer Biology Program 2015-2016 Jared Hooks, Cancer Biology Program2012-2017 Pavlina Todorova, Cancer Biology Program |
| Qualifying examination committees |
| 2008 | Laura Payton |
| 2009 | Michael Torres |
| 2010 | Christen Gravlin |
| 2011 | Suzie Hight |
| 2012 | Mariam El-Ashmawy |
| 2013 | JiMi Kim (Chair of the Qualifying Committee) |
| 2014 | Sachith Gallolu Kankanamalage (Chair of the Qualifying Committee) |
| 2015 | Aubhishek Zaman (Chair of the Qualifying Committee) |
| Committees concerned with medical and graduate student education |
| NA |  |
|  |  |
| Graduate student rotations |
| 2010 | Alejandro D’Brot |
| 20102011201120172019 | Gamze BulutJerfiz ConstanzoJonathan CooperEliot BlattJullianna Korns |
| Medical student rotations |
| NA |  |
|  |  |
| Graduate student trainees |
| 2007-2009 | Georgia Konstantinidou (visiting Graduate Student, University of Camerino, Italy) |
| 2011-2016 | Jerfiz Constanzo |
| Postgraduate medical education (graduate & continuing medical education) |
| 2007 | Hematology/Oncology Fellowship Training program: Oncogenic networks seminar |
| 2008 | Hematology/Oncology Fellowship Training program: NSCLC modeling and preclinical drug testing |
| 2011 | Hematology/Oncology Fellowship Training program: Preclinical Mouse Models of Lung Cancer |
| 2012 | Hematology/Oncology Fellowship Training program: Preclinical Mouse Models of Lung Cancer seminar  |
| 2013 | Hematology/Oncology Fellowship Training program: Acute Promyeolocytic leukemia: Molecular pathogenesis and rationale therapies. |
| 2014 | Hematology/Oncology Fellowship Training program: Oncogenes and Cancer |
| 2016 | Hematology/Oncology Fellowship Training program: Oncogene addiction |
| Postdoctoral trainees |
| 2007-20082009-20112008-20132009-20132008-20142013-20172013-20162014-present2016-present2016-present2020- | Alessandro Rimessi, Ph.D. Post-doctoral FellowMo Chen, Ph.D. Post-doctoral FellowKatja Schuster, Ph.D. Post-doctoral FellowGeorgia Konstantinidou, Ph.D Post-doctoral FellowAndrea Rabellino, Ph.D Post-doctoral FellowMahesh Padanad, Ph. D Post-doctoral FellowKejing Tang Sun Yat-Sen Visiting ScholarSmita Rindhe, Ph.D. Post-doctoral FellowCaterina Bartolacci, Ph.D. Post-doctoral FellowCristina Andreani, Ph.D. Post-doctoral FellowYasmin El Gammal Post-doctoral Fellow |
|  |  |

**Invited Lectures**

|  |  |  |
| --- | --- | --- |
| Year(s) | Title | Location |
| International |
| 2009 | Dual PI3K/mTOR blockade is an effective radio-sensitizing strategy for the treatment of non-small cell lung cancer harboring K-Ras mutations. | Mechanisms & Models of Cancer Meeting. Salk Institute. La Jolla, CA. USA. |
| 2010 | The PIAS1 SUMO E-3 ligase regulates tumorigenesis through SOMOylation of the PML tumor suppressor. | Mechanisms and Models of Cancer. Cold Spring Harbor Laboratory. NY. August 17-21, 2010.  |
| 2010 | Dual PI3K/mTOR blockade is an effective radio sensitizing strategy for the treatment of NSCLC harboring K-RAS mutations | International Association for the Study of Lung Cancer, 10th Annual Targeted Therapies of Lung Cancer Meeting. Santa Monica, CA |
| 2012 | The Talented PIAS1 regulates PML and PML-RARA | Heinrich Pette Institute, Hamburg, Germany |
| 2012 | RHOA-FAK is a required signaling axis for the maintenance of K-Ras driven adenocarcinoma  | Department of Pathology, University of Hamburg, Germany |
| 2013 | Metabolic and Signaling Vulnerabilities of KRAS-driven lung adenocarcinoma | European Institute of Oncology, Milano, Italy. Grand Rounds. |
| 2013 | Identification of Focal Adhesion kinase (FAK) as a Therapeutic Target in Mutant KRAS Lung Cancer | 3rd Symposium Mechanisms and Models of Cancer. Salk Institute, La Jolla. CA. August 7-10, 2013 |
| National |
| 2013 | Metabolic and Signaling Vulnerabilities of KRAS-driven lung adenocarcinoma | Division of Hematology/Oncology. University of California, Irvine, CA. |
| 2013 | Metabolic and Signaling Vulnerabilities of KRAS-driven lung adenocarcinoma | Division of Hematology/Oncology. UT Health Science Center. San Antonio, TX. |
| 2013 | Genotype Specific Cancer Vulnerabilities: the case of PML-RARA and Mutant KRAS | Indiana University Simon Cancer Center |
| 2013 | Genotype Specific Cancer Vulnerabilities: the case of PML-RARA and Mutant KRAS | Hematology Grand Rounds, Vanderbilt University medical Center |
| 2013 | Genotype Specific Cancer Vulnerabilities: the case of PML-RARA and Mutant KRAS | Case Comprehensive Cancer Center Seminar Series |
| 2013 | Identification of Focal Adhesion kinase (FAK) as Therapeutic Target in KRAS Lung Cancer | Lung Spore Workshop. National Cancer Institute. Rockville, MD. July 11-12, 2013.  |
| 2013 | Genotype Specific Cancer Vulnerabilities: the case of PML-RARA and Mutant KRAS | City of Hope Comprehensive Cancer Center. Department of Hematology and Hematopoietic Cell Transplantation. Duarte, CA. |
| 2013 | PML Nuclear Bodies: a toolbox to identify Novel Oncogenic Networks | City of Hope Comprehensive Cancer Center. Department of Hematology and Hematopoietic Cell Transplantation. Duarte, CA. |
| 2014 | Acyl-CoA Synthetase Long-chain Family Member 3 is Required for Mutant KRAS Lung Cancer  | Lung Cancer SPORE Meeting, Rockville, MD, 7/25-26/2014.  |
| 2015 | Focal adhesion kinase is a Therapeutic target in KRAS lung cancer. 15° Annual Targeted Therapies of Lung Cancer Meeting.  | International Association for the Study of Lung Cancer (IASLC). The Fairmont Miramar Hotel, Santa Monica, CA. February 18-21, 2015. |
| 2015 | Pharmacologic inhibition or genetic ablation of Focal adhesion kinase (FAK) is radiosensitizing in mutant KRAS lung cancer.  | Lung Cancer SPORE Workshop. Rockville, MD. June 15-16, 2015.  |
| 2016  | Fatty Acid Metabolism is a Vulnerability of Mutant KRAS Lung Cancer | Institute of Applied Cancer Science, MD Anderson Cancer Center, Houston, TX. May 17, 2016 |
| 2016 | Novel Targetable Vulnerabilities of Mutant KRAS Lung Cancer | University of Iowa, Carver College of Medicine, 11/30/2016 |
| 2017 | Novel Targetable Vulnerabilities of Mutant KRAS Lung Cancer | University of Cincinnati College of Medicine, 3/10/2017 |
| 2017 | Lipid Metabolism is a Novel Vulnerability of Mutant KRAS Lung Cancer | Ohio State University, Translational Therapeutic Program, 4/6/2017 |
| Regional/Local |
| 2007 | Role of PML degradation in tumor suppression | UTSW Radiology Grand Rounds |
| 2007 | NSCLC modeling and preclinical drug testing | UTSW Hamon Center Research Conference |
| 2008 | Identification of vulnerabilities of lung cancer cells | UTSW Simmons Cancer Center Cancer Cell Networks meeting |
| 2008 | Modeling Lung Cancer in the Mouse | UTSW Internal Medicine Department Conference |
| 2009 | Inhibition of PI3K signaling as a therapeutic strategy in lung cancer | UTSW Lung Cancer Disease-Oriented Team |
| 2009 | PI3K signaling in lung cancer pathogenesis | UT Southwestern Medical Center, Metabolism Research Seminar |
| 2010 | Deconstructing oncogenic K-RAS induced tumorigenesis | UT Southwestern Medical Center, Department of Pathology Grand Rounds |
| 2010 | Development of a novel targeted therapy for acute and chronic leukemias | Texas Leukemia, Dallas, TX |
| 2011 | Deconstruction of oncogenic networks in APL sets the stage for the development of novel targeted cancer therapies | UTSW Medicine Grand Rounds |
| 2011 | Deconstruction of oncogenic networks in APL sets the stage for the development of novel targeted cancer therapies | Grand Rounds: UTSW MD Ph.D. Training Program |
| 2011 | Deconstruction of oncogenic K-RAS induced replicative senescence | UTSW Hamon Center Research Conference  |
| 2011 | Selective targeting of the mTORC1/2 protein Kinase complex in TKI resistant CML | UTSW Hematologic Malignancies Retreat |
| 2011 | Focal Adhesion kinase is essential for the maintenance of oncogenic K-RAS NSCLC deficient for INK4a/ARF | UTSW Lung Cancer Disease-Oriented Team |
| 2012 | RHOA-FAK is a Required Signaling Axis for the Maintenance of K-RAS-driven Adenocarcinomas | UTSW Lung Cancer SPORE Seminar |
| 2013 | Acute promyelocytic Leukemia: pathogenesis and modern treatment options | UTSW BMT/hematologic malignancies DOT |
| 2013 | The Multifaceted Role of the Talented PML in Tumorigenesis | UTSW Hamon Center Research Conference |
| 2013 | Focal adhesion kinase is a therapeutic target in mutant KRAS lung adenocarcinomas | 1st Annual Summit on Practical and Emerging Approaches for Lung Cancer. December 14-15, 2013, Ritz Carlton, Dallas, TX. |
| 2014 | Chasing the Achilles’ Heel of Cancer: the Case of Acute Promyelocytic Leukemia. | American Cancer Society Research Symposium: Conversation about cancer. Collins Center at Southern Methodist University, 4/29/2014. |
| 2014 | ACSL3 in KRAS-Driven lung Tumorigenesis | Simmons Cancer Center Physician-scientist meeting. UTSW, 4/10/2014 |
| 2016 | Fatty Acid Metabolism is a Vulnerability of Mutant KRAS Lung Cancer | Children Research Institute of UT Southwestern, 5/4/2016 |
| 2016 | Fatty Acid Metabolism is a Vulnerability of Mutant KRAS Lung Cancer | UTSW Hamon Center Research Conference, 9/15/2016 |
| 2017 | Fatty Acid Metabolism is a Novel Vulnerability of Mutant KRAS Lung Cancer | Simmons Cancer Center Physician-scientist meeting. UTSW, 7/6/2017. |
| 2019 | Fatty Acid Metabolism is a Therapeutic Target in Mutant KRAS Lung Cancer | Precision Genomics Midwest, Cincinnati, 5/10/2019 |
| 2019 | Deconstruction of Oncogenic networks in APL sets the Stage for the development of Novel Targeted Therapies | University of Cincinnati College of Medicine, Medicine Grand Rounds, 11/18/2019 |
| 2019 | Mutant KRAs hijacks fatty Acid Metabolism in Lung Cancer | Wright State University, Department of Biochemistry and Molecular Biology, Dayton. OH. 10/17/2019. |

**Technological and Other Scientific Innovations**

|  |
| --- |
| Innovation |
| Patent, if any, pending or awarded /If described in print/on web, provide citation |

|  |
| --- |
| Inhibition of Hepatitis B Replication. Patent # WO09700698A1 Inhibition of Viral Replication. Patent # WO 09809649A1 |
|  |

**Bibliography**

**Peer-Reviewed Publications**

Investigative Reports

|  |  |
| --- | --- |
|  | C. Pasquinelli, M. Melegari, E. Villa, M. Seidenari, **P. P. Scaglioni**, C. Tiribelli, L. S. Croce’, A. Ferrari, F. Manenti. Detection of Hepatitis B Virus transcripts in patients with chronic liver disease. J. Hepatol. 1990. 10 : 180-185. |
|  | C. Pasquinelli, M. Melegari, E. Villa, **P. P. Scaglioni**, M. Seidenari, N. Mongiardo, B. De Rienzo, F. Manenti. Hepatitis B virus infection of peripheral blood mononuclear cells is common in acute and chronic hepatitis. J. Med. Virol. 1990. 31 : 135-140. |
|  | E. Villa, M. Melegari, **P. P. Scaglioni**, P. Trande, P. Cesaro, F. Manenti. Hepatocellular carcinoma: risk factors other than HBV. Ital. J. Gastroenterol. 1991. 23: 457-60. |
|  | E. Villa, M. Melegari, I. Ferretti, C. Vecchi, **P. P. Scaglioni**, P. Trande, M. De Palma, F. Manenti. HCV RNA in serum of asyntomatic blood donors involved in post-transfusion hepatitis (PTH). J. Hepatol. 1991. 13:256-260. |
|  | M. Melegari, M. C. Jung, R. Schneider, R. T. Santantonio, S. Bagnulo, N. Luchena, G. Pastore, G. Pape, **P. P. Scaglioni**, E. Villa, H. Will. Conserved core protein sequences in hepatitis B virus infected patients without anti-HBc. J. Hepatol. 1991. 13 : 187-192. |
|  | M. Melegari, **P. P. Scaglioni**, C. Pasquinelli, F. Manenti, E. Villa. Hepatitis B virus specific transcripts in peripheral blood mononuclear cells. Arch. Virology. 1992. 4: 46-49. |
|  | E. Villa, M. Melegari, **P. P. Scaglioni**, F. Manenti. Presence of HCV RNA in serum of asyntomatic blood donors involved in post-transfusion hepatitis (PTH). Arch. Virolology. 1992. 4: 247-248. |
|  | **P. P. Scaglioni**, M. Melegari and J. R. Wands. Characterization of Hepatitis B Virus core mutants that inhibit viral replication. Virology. 1994. 205: 112-120. |
|  | **P. P. Scaglioni,** M. Melegari, M. Takahashi, J. Roy Chowdhury, and J. R. Wands. Use of dominant negative mutants of the hepadnaviral core protein as antiviral agents. Hepatology. 1996. 24: 1010-1017. |
|  | **P. P. Scaglioni\***, M. Melegari\*, and J. R. Wands. (\*First authorship shared) Posttranscriptional regulation of hepatitis B virus replication by the precore protein. Journal of Virology. 1997. 71: 345-353. |
|  | **P. P. Scaglioni\***, M. Melegari\*, and J. R. Wands. (\*First authorship shared) Biologic properties of Hepatitis B viral genomes with mutations in the precore promoter and precore open reading frame. Virology. 1997. 233: 374-381. |
|  | M. Melegari\*, **P. P. Scaglioni\***, and J. R. Wands. (\*First authorship shared) The small envelope protein is required for secretion of a naturally occurring HBV pre-S1 mutant. Journal of Virology. 1997. 71: 5449-5454. |
|  | J. R. Wands, M.Geissler, J. Zu Putlitz, H. Blum, F. Von Weizsacker, L. Mohr, S. K. Yoon, M. Melegari, and **P. P. Scaglioni.** Nucleic acid-based antiviral and gene therapy of chronic hepatitis B infection. Journal of Gastroenterology and Hepatology. 1997. 12: 354-69. |
|  | M. Melegari\***, P. P. Scaglioni\***, and J. R. Wands. (\*First authorship shared) Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology. 1998. 27: 628-33. |
|  | M. Melegari\***, P. P. Scaglioni\***, and J. R. Wands. (\*First authorship shared) Cloning and characterization of a novel hepatitis B virus x binding protein that inhibits viral replication. Journal of Virology. 1998. 72: 1737-43. |
|  | L. Mohr, S. K. Yoon, S. J. Eastman, Q. Chu, R. K. Scheule, **P. P. Scaglioni**, M. Geisler, T. Heintges, H. E. Blum, J. R. Wands. Cationic liposome-mediated gene delivery to the liver and to hepatocellular carcinoma in mice. Human Gene Therapy. 2001. 12: 799-80. |
|  | C. Gurrieri, P. Capodieci, R. Bernardi, **P. P. Scaglioni**, K. Nafa, L.J. Rush, D.A. Verbel, C. Cordon-Cardo, P. P. Pandolfi. Loss of the tumor suppressor PML in human cancers of multiple histologic origins. J. Natl. Cancer Inst. 2004. 96: 269-79. |
|  | R. Bernardi, **P. P. Scaglioni**, S. Bergmann, H.F. Horn, K. H. Vousden and P. P. Pandolfi PML regulates p53 stability through nucleolar sequestration of Mdm2. Nat. Cell. Biol. 2004. 6:665-672. |
|  | H. Matsushita, **P.P.** **Scaglioni**, M. Bhaumik,E.M. Rego, L.F. Cai, Hayato Miyachi, A. Kakizuka, W.H. Miller, P.P. Pandolfi. In vivo analysis of the role of aberrant histone deacetylase recruitment and RARalpha blockade in the pathogenesis of acute romyeolocytic leukemia. J Exp Med. 2006. 17:821-828. |
|  | L.C. Trotman, A. Alimonti, **P.P. Scaglioni**, J.A. Koutcher, C. Cordon-Cardo, P.P. Pandolfi. Identification of a tumour suppressor network opposing nuclear Akt function. Nature. 2006. 25:523-527. |
|  | **P.P Scaglioni**, T. Yung, L. F. Cai, H. Erdjument-Bromage, P. Tempst, J. Teruya-Feldstein, P. P. Pandolfi.A CK2-dependent pathway for PML degradation upon cellular and oncogenic stress. Cell. 2006. 126:269-283. |
|  | T.H. Shen, H.K. Lin, **P.P. Scaglioni**, T.M. Yung, P.P. Pandolfi. The Mechanisms of PML-Nuclear Body Formation. Mol Cell. 2006. 24:331-9. |
|  | **P.P. Scaglioni**, T.M. Yung, S.C. Choi, C.Baldini, G. Konstantinidou, P.P. Pandolfi. CK2 mediates phosphorylation and ubiquitin-mediated degradation of the PML tumor suppressor. Mol Cell Biochem. 2008. 316:149-54. |
|  | G. Konstantinidou, E. Bey, A. Rabellino, K. Schuster, M.S. Maira, A. Gazdar, D. Boothman, **P. P. Scaglioni**. Dual PI3K/mTOR blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer. Cancer Research. 2009. 69:7644-52. |
|  | J.P. Sullivan, M. Spinola, M. Dodge, M.G. Raso, C. Behrens, B. Gao, K. Schuster, C. Shao, J.E. Larsen, L.A. Sullivan, S. Honorio, Y. Xie, **P.P. Scaglioni**, J.M. DiMaio, A.F. Gazdar, J.W. Shay, I.I. Wistuba, J.D. Minna. Aldehyde dehydrogenase activity selects for Notch signaling dependent non-small cell lung cancer stem cells. Cancer Research. 2010. 70:9937-48. |
|  | H.V. Naina, D. Levitt, M. Vusirikala, L.D. Anderson Jr, **P.P. Scaglioni**, A. Kirk, R.H. Collins Jr. Successful treatment of relapsed and refractory extramedullary acute romyeolocytic leukemia with tamibarotene. J Clin Oncol. 2011. 29:e534-6. |
|  | **P. P. Scaglioni**, L. F. Cai, S.M. Majid, T.M. Yung, N.D. Socci, S.C. Kogan, L. Kopelovich, P.P. Pandolfi. Treatment with 5-Azacytidine Accelerates Acute Promyelocytic Leukemia Leukemogenesis in a Transgenic Mouse Model. Genes Cancer. 2011. 2: 160–165. |
|  | K. Schuster, J. Zheng, A.A. Arbini, C.C. Zhang, **P.P. Scaglioni**. Selective targeting of the mTORC1/2 protein complexes leads to antileukemic effects in vitro and in vivo. Blood Cancer. 2011. 1, e34. Doi:10.1038/bcj.2011.30. |
|  | **P.P. Scaglioni**\*, A. Rabellino, T.M. Yung, R. Bernardi, S. Choi, G. Konstantinidou, C. Nardella, K. Cheng, P.P. Pandolfi\*. \*Co-corresponding authors. Translational-dependent mechanisms lead to PML upregulation and mediate oncogenic K-RAS induced cellular senescence. EMBO Molecular Medicine. 2012. 4:594-602. Doi: 10.1002/emmm.201200233. |
|  | A. Rabellino, B. Carter, G. Konstantinidou, S.Y. Wu, A. Rimessi, L. A. Byers, J.V. Heymach, Luc Girard, C.M Chiang, J. Teruya-Feldstein and **P. P. Scaglioni**. The SUMO E3-ligase PIAS1 regulates the tumor suppressor PML and its oncogenic counterpart PML-RARA. Cancer Research. 2012. 72: 2275-2284. |
|  | G. Konstantinidou, A. Heguy, F. Torti, G. Ramadori, K. Kangasniemi, R.E. Ramirez, Y. Cai, C. Behrens, M.T. Dellinger, I.I. Wistuba, R.A. Brekken, J. Teruya-Feldstein and **P.P. Scaglioni**. RHOA-FAK signaling is required for the maintenance of K-RAS-driven adenocarcinomas. Cancer Discovery, 2013. 3:444-57. Article **featured in World Biomedical Frontiers**. |
|  | K. Schuster, N. Venkateswaran, A. Rabellino, L. Girard, S. Peña-Llopisand **P.P. Scaglioni**. Loss of the *CDKN2AB* locus promotes mutant *KRAS* lung tumorigenesis. Molecular Cancer Research, 2014. 12:912-23. |
|  | G. Ramadori, G. Konstantinidou, N. Venkateswaran, T. Biscotti, L. Morlock, M. Galié, N.S. Williams, M. Luchetti, A. Santinelli, **P.P. Scaglioni\*** and R. Coppari\*. Diet-Induced Unresolved ER Stress Hinders KRAS-Driven Lung Tumorigenesis. Cell Metabolism. 2015. 21:117-25. \* Corresponding author. |
|  | K.N. Rajagopalan, R.A. Egnatchik, M.A. Calvaruso, A.T. Wasti,M.S. Padanad, L.K. Boroughs, B. Ko, C.T. Hensley, M. Acar, Z. Hu, L. Jiang, J.M. Pascual, **P.P. Scaglioni** and R.J. DeBerardinis. Metabolic plasticity maintains proliferation in pyruvate dehydrogenase deficient cells. Cancer Metab. 2015. 3, 7. |
|  | G. Chakrabarti, Z.R. Moore, X. Luo, M. Ilcheva, A. Ali, M.S. Padanad, Y. Zhou, Y. Xie, S. Burma, **P.P. Scaglioni**, L.C. Cantley, R.J. DeBerardinis, A.C. Kimmelman, C.A. Lyssiotis, D.A. Boothman. Targeting glutamine metabolism sensitizes pancreatic cancer to PARP-driven metabolic catastrophe induced by ß-lapachone. Cancer Metab. 2015. 3, 12. |
|  | J.D. Constanzo, M. Deng, S. Rindhe, K.J. Tang, C.C. Zhang, **P.P. Scaglioni**. [Pias1 is essential for erythroid and vascular development in the mouse embryo.](http://www.ncbi.nlm.nih.gov/pubmed/27155222) Dev Biol. 2016. 415:98-110.  |
|  | K.J. Tang, J.D. Constanzo, N. Venkateswaran, M. Melegari, M. Ilcheva, J.C. Morales, F. Skoulidis, J.V. Heymach, D.A. Boothman, **P.P. Scaglioni**. Focal Adhesion Kinase regulates the DNA damage response and its inhibition radiosensitizes mutant KRAS lung cancer. Clin Cancer Res. 2016 May 24. Pii: clincanres.2603.2015.  |
|  | J.D. Constanzo, K.J. K.J. Tang, S. Rindhe, M. Melegari, H. Liu, X. Tang, J. Rodriguez-Canales, I. Wistuba, P.P. Scaglioni. PIAS1-FAK Interaction Promotes the Survival and Progression of Non-Small Cell Lung Cancer. Neoplasia. 2016. 18:282-93. |
|  | A. Rabellino, M. Melegari, V.S. Tompkins, W. Chen, B.G. Van Ness, J. Teruya-Feldstein, M. Conacci-Sorrell, S. Janz, **P.P. Scaglioni**. PIAS1 Promotes Lymphomagenesis through MYC Upregulation. Cell Rep. 2016. Cell Rep. 2016. 15:2266-78. |
|  | M.S. Padanad, G. Konstantinidou, N. Venkateswaran, M. Melegari, S. Rindhe, M. Mitsche, C. Yang, K. Batten, K.E. Huffman, J. Liu, X. Tang, J. Rodriguez-Canales, N. Kalhor, J.W. Shay, J.D. Minna, J. McDonald, I. Wistuba, R.J. DeBerardinis, P.P. Scaglioni. Cell Rep. 2016. Jul 27.  |
|  | J. Kim, E. McMillan, H.S. Kim, N. Venkateswaran, G. Makkar, J. Rodriguez-Canales, P. Villalobos, J.E. Neggers, S. Mendiratta, S. Wei, Y. Landesman, W. Senapedis, E. Baloglu, C.B Chow, R.E. Frink, B. Gao, M. Roth, J.D. Minna, D. Daelemans, I.I. Wistuba, B.A. Posner, **P.P. Scaglioni**, M.A. White. XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer. Nature. 2016. 538:114-117. |
|  | V. Tumati, L. Trivedi, H.C. Li, P. Patel, **P.P. Scaglioni**, M. Vusirikala, N. Sadeghi, S. Rizvi, W. Chen, J. Wachsmann, R. Collins Jr., N.B. Desai. Patterns of Failure in Patients With Double Hit or Double Expressor Lymphomas: Implications for Radiation Therapy. Int J Radiat Oncol Biol Phys. 2018. 100:1126-1132. |
|  | M.C. Lafita-Navarro, M. Kim, N. Borenstein-Auerbach, N. Venkateswaran, Y.H. Hao, R. Ray, T. Brabletz, **P.P. Scaglioni**, J.W. Shay, M. Conacci-Sorrell.The aryl hydrocarbon receptor regulates nucleolar activity and protein synthesis in MYC-expressing cells. Genes Dev. 2018. 32:1303-1308. |
|  | D.E. Gerber, D.R. Camidge, D. Morgensztern, J. Cetnar, R.J. Kelly, S.S. Ramalingam, D.R. Spigel, W. Jeong, **P.P. Scaglioni**, S. Zhang, M. Li, D.T. Weaver, L. Vaikus, M. Keegan, J.C. Horobin, T.F. Burns. Phase 2 Study of the Focal Adhesion Kinase Inhibitor Defactinib (VS-6063) in Previously Treated Advanced KRAS Mutant Non-Small Cell Lung Cancer. 2020. Lung Cancer. 139:60-67. |

 Reviews, Book Chapters, Monographs and Editorials

|  |  |
| --- | --- |
|  | 1. J. R. Wands, M. Geissler, J. Zu Putlitz, H. Blum, F. Von Weizsacker, L. Mohr, S. K. Yoon, M. Melegari, **P. P. Scaglioni.** Nucleic acid-based antiviral and gene therapy of chronic hepatitis B infection. Journal of Gastroenterology and Hepatology. 1997. 12: 354-69. |
|  | **P. P. Scaglioni** and P. P. Pandolfi. Taking apart a cancer protein. Nature. 2003. 426: 512-13. |
|  | **P.P. Scaglioni** and P.P. Pandolfi. The theory of APL revisited. Acute Promyelocytic Leukemia: Molecular Genetics, Mouse Models and Targeted Therapy. Current Topics in Microbiology and Immunology. 2006. 313: 85-100. |
|  | A. Rabellino and **P.P. Scaglioni.** Many roads lead to PML degradation. Frontiers in Molecular and Cellular Oncology. 2013. 3:60. |
|  | A. Rabellino, C. Andreani and **P.P. Scaglioni**. The role of the PIAS SUMO E3 ligases in Cancer. Cancer research. 2017. 77:1542-1547. |
|  | A. Gupta, J.M. Saltarski, M.A. White, **P.P. Scaglioni**, D.E. Gerber. Therapeutic Targeting of Nuclear Export Inhibition in Lung Cancer. J Thorac Oncol. 2017. S1556-0864(17)30466-5. |
|  | A.Rabellino, Andreani C. and **P.P. Scaglioni**. Roles of Ubiquitination in the Regulation of angiogenesis. Current Issues Mol. Biol. 2020. 35:109-126. |

Meeting Proceedings

|  |  |
| --- | --- |
|  | C. Pasquinelli, M. Melegari, M. Seidenari, **P. P. Scaglioni**, A. Ferrari, C. Tiribelli, F. Manenti, E. Villa. Hepatitis B virus transcription in chronic liver disease. International Conference: "Current Trends in Chronically Evolving Viral Hepatitis". Fiuggi, Italy. October 5-8, 1988. (i) IV International Symposium on Viral Hepatitis. Madrid, Spain. January 26-27, 1989. (ii) Workshop on "Molecular Biology of Hepatitis B Viruses". Sestrieres, Italy. April, 6-9, 1989. |
|  | C. Pasquinelli, M. Melegari, M. Seidenari, **P. P. Scaglioni**, A Ferrari, M. Malagoli, F. Manenti, E. Villa. Trascrizione del virus dell' epatite B in patologia epatica cronica. SIC Societa' Italiana di Cancerologia. VI Riunione Nazionale di Oncologia Sperimentale e Clinica. Rome, Italy. November 20-23, 1988. Tumori. 1988: 74,20. |
|  | C. Pasquinelli, **P. P. Scaglioni**, M. Seidenari, M. Melegari, F. Manenti, E. Villa. Southern, Northern and Polymerase Chain Reaction (PCR) study of the HBV sequences in peripheral blood mononuclear cells. IV International Symposium on Viral Hepatitis. Madrid, Spain. January, 26-27, 1989. (i) XVIIIth Meeting of the European Tumor Virus Study Group. Sundbyholm's Castle, Sweden. April 30-May 4, 1989. (ii) Molecular Biology of Hepatitis B viruses. Cold Spring Harbor, NY. September 25-28, 1989. (iii) VIII International Congress of Liver Disease. Infectious Disease of the Liver. Basel, Switzerland. October 12-14, 1989. |
|  | Pasquinelli, **P. P. Scaglioni**, M. Seidenari, M. Melegari, N. Mongiardo, B. De Rienzo, F. Manenti, E. Villa. HBV DNA in peripheral blood mononuclear cells of acute hepatitis: comparison between southern blot analysis and polymerase chain reaction. Workshop on Molecular Biology of Hepatitis B Viruses. Sestrieres, Italy. April 6-9, 1989. (i) AISF Associazione Italiana per lo Studio del Fegato. XXII Riunione generale annuale. Rome, Italy. June 8-9, 1989. Ital. J. Gastroenterol. 1989. 21: 104. (ii) EASL 24th Meeting of the European Association for the Study of the Liver. Munich, Germany. August 28-September 2, 1989. |
|  | C. Pasquinelli, **P. P. Scaglioni**, M. Melegari, E. Villa, F. Manenti. Hepatitis delta virus (HDV) and hepatitis B virus (HBV) coreplication result in a rapidly progressive disease. EASL 24th Meeting of the European Association for the Study of the Liver. Munich, Germany. August 28-September 2, 1989. J. Hepatol. 1989. 9: S220. (i) VII International Congress of Liver Disease. Infectious Diseases of the Liver. Basel, Switzerland. October 12-14, 1989. |
|  | **P. P. Scaglioni**, C. Pasquinelli, M. Melegari, F. Manenti, E. Villa. Presenza di sequenze HBV DNA in linfociti di pazienti con patologia epatica: paragone tra analisi di Southern e Reazione Polimerasica di Catena. VII Riunione Nazionale di Oncologia Sperimentale e Clinica. Genoa, Italy. November 19-22, 1989. Tumori. 1989. 75: S133. |
|  | E. Villa, M. Melegari, **P. P. Scaglioni**, M. Marrazzi, I. Ferretti, C. Vandelli, C. Pasquinelli, F. Manenti. Pattern of envelope proteins in the liver of patients before and after development of hepatocellular carcinoma (HCC). II Workshop on Molecular Biology of Hepatitis B Viruses. Sestrieres, Italy. April 21-24, 1990. (i) AISF Associazione Italiana per lo Studio del Fegato. Rome, Italy. May 31-June 2, 1990. Ital. J. Gastroenterol. 1990. 22: 182. |
|  | M. Melegari, **P. P. Scaglioni**, C. Pasquinelli, F. Manenti, E. Villa. HBV specific RNA detected by PCR in PBMCs. Molecular Biology of Hepatitis B Viruses. La Jolla, CA. August, 5-9 1990. |
|  | M. Melegari, **P. P. Scaglioni**, C. Morelli, L. Gandolfi, C. Pasquinelli, F. Manenti, E. Villa. Presence of HCV genome in HCC patients. EASL 25th Meeting of the European Association for the Study of the Liver. Budapest, Hungary. October 3-6,1990. (i) Second international Conference-Current Trends in Chronically Evolving Hepatitis. Siena, Italy. October 24-25,1990. (ii) Consensus Conference on Hepatocellular Carcinoma. Milan, Italy. November 12-14, 1990. Ital. J. Gastroenterol. 1990. 22: 234 |
|  | E. Villa, M. Melegari, **P. P. Scaglioni**, C. Vecchi, I. Ferretti, M. De Palma, F. Manenti. HCV RNA in asyntomatic blood donors. EASL 25th Meeting of the European Association for the Study of the Liver. Budapest, Hungary. October 3-6, 1990. (i) Second International Conference-Current Trends in Chronically Evolving Hepatitis. Siena, Italy. October 24-27, 1990. |
|  | **P. P. Scaglioni**, M. Melegari, F. Manenti, E. Villa. Evidence of HBV replication in PBMCs of chronically infected patients. Second International Conference-Current Trends in Chronically Evolving Hepatitis. Siena, Italy. October 24-27, 1990. |
|  | M. Melegari, C. Jung, T. Santantonio, G. Pastore, N. Luchena, S. Bagnulo, **P. P. Scaglioni**, E. Villa, H. Will. The hepatitis B virus core protein is conserved in patients without anti-HBc production. Second International Conference-Current Trends in Chronically Evolving Hepatitis. Siena, Italy. October 24-27, 1990. (i) Genetic heterogeneity of Hepatitis Viruses. Clinical implications. Sestriere, Italy. April 5-7,1991. |
|  | **P. P. Scaglioni**, M. Melegari, C. Morelli, L. Gandolfi, E. Villa. Presenza del genoma dell'epatite C in pazienti con epatocarcinoma. VIII Riunione Nazionale di Oncologia Sperimentale e Clinica. Bologna, Italy. November 25-26,1990. Tumori. 1990. 76: S24. |
|  | M. Melegari, **P. P. Scaglioni**, F. Manenti, E. Villa. Trascritti HBV specifici determinati in PCR nelle cellule mononucleate del sangue periferico (CMSP). VIII Riunione Nazionale di Oncologia Sperimentale e Clinica. Bologna, Italy. November 25-26, 1990. Tumori 1990. 76: S25. |
|  | **P. P. Scaglioni** and C. Seeger. Characterization of WHV core mutants that inhibit viral replication. Molecular Biology of Hepatitis B Viruses. La Jolla, CA. August 30-September 3, 1992. |
|  | **P. P. Scaglioni**, M. Melegari and J. R. Wands. Characterization of hepatitis B virus core mutants that inhibit viral replication. Molecular Biology of Hepatitis B Viruses. Paris, France. October 3-6, 1994. (i) The American Association For the Study of Liver Disease 45th Annual Meeting Chicago, IL. November 11-15, 1994. |
|  | M. Melegari, **P. P. Scaglioni** and J. R. Wands. Characterization of a liver specific HBx interacting protein. Molecular Biology of Hepatitis B Viruses. La Jolla, CA. July 23-27, 1995. (i) ) The American Association For the Study of Liver Disease 46th Annual Meeting Chicago, IL. November 3-7, 1995. |
|  | **P. P. Scaglioni**, M. Melegari and J. R. Wands. Use of dominant negative hepadnaviral core mutants as antiviral agents. Molecular Biology of Hepatitis B Viruses. La Jolla, CA. July 23-27, 1995. (i) The American Association For the Study of Liver Disease 46th Annual Meeting Chicago, IL. November 3-7, 1995. |
|  | M. Melegari, **P. P. Scaglioni** and J. R. Wands. Molecular identification and characterization of Xip as a hepatitis B x protein (HBx) interactor that downregulates HBV replication. Molecular Biology of Hepatitis B Viruses. Cold Spring Harbor Laboratory. NY. September 18-22, 1996. (i) The American Association For the Study of Liver Disease 47th Annual Meeting Chicago, IL. November 8-12, 1996. |
|  | **P. P. Scaglioni**, M. Melegari and J. R. Wands. Post-Transcriptional regulation of HBV replication by the precore protein. Molecular Biology of Hepatitis B Viruses. Cold Spring Harbor Laboratory. NY. September 18-22, 1996. (i) The American Association For the Study of Liver Disease 47th Annual Meeting Chicago, IL. November 8-12, 1996. |
|  | L. Mohr, S. K. Yoon, S. J. Eastman, R. K. Scheule, Q. Chu, **P. P. Scaglioni**, T. Heintges, and J. R. Wands. In vivo gene delivery to the liver and to intrahepatic tumors with cationic liposomes in nude mice. The American Association For the Study of Liver Disease 48th Annual Meeting Chicago, IL. November 7-11, 1997. |
|  | L. Mohr, S. K. Yoon, S. J. Eastman, R. K. Scheule, Q. Chu, **P. P. Scaglioni**, T. Heintges, and J. R. Wands. In vivo gene delivery to the liver and to intrahepatic tumors with cationic liposomes in nude mice. The American Association For the Study of Liver Disease 48th Annual Meeting Chicago, IL. November 7-11, 1997. |
|  | S.K. Yoon, **P. P. Scaglioni**, L. Mohr, M. Melegari, D. Armentano, S. delaMonte, and J. R. Wands. Adenovirus mediated gene transfer and expression in mouse liver. The American Association For the Study of Liver Disease 48th Annual Meeting Chicago, IL. November 7-11, 1997. |
|  | M. Melegari, **P. P. Scaglioni** and J. R. Wands. Hepatitis B virus mutants induced by 3TC and Famciclovir are replication defective. Molecular Biology of Hepatitis B Viruses. Paris, France. September 22-25, 1997. (i) The American Association For the Study of Liver Disease 48th Annual Meeting Chicago, IL. November 7-11, 1997. |
|  | **P. P. Scaglioni**, M. Melegari, and J. R. Wands. Biologic properties of Hepatitis B viral genomes with mutations in the precore promoter and precore open reading frame. The American Association For the Study of Liver Disease 48th Annual Meeting. Chicago, IL. November 7-11, 1997. |
|  | M. Melegari, **P. P. Scaglioni** and J.R. Wands. Hbx acts as a weak transactivator when expressed by HBV replication competent genomes. Molecular Biology of Hepatitis B Viruses. La Jolla, CA. July 23-27, 1998. (i) The American Association For the Study of Liver Disease 49th Annual Meeting. Chicago, IL. November 6-10, 1998. |
|  | R. Bernardi, S. Grisendi, P. Salomoni, **P. P. Scaglioni**, P. P. Pandolfi. The promyelocytic leukemia protein, PML, localizes to the nucleolus after DNA damage, interacts with Mdm2 and promotes p53 stability. The American Society of Hematology, 2002 Annual Meeting. Philadelphia, PA. December 6-10, 2002. |
|  | . H. Matsushita, **P. P. Scaglioni**, A. C. Changou, M. A. Leversha, P. P. Pandolfi. RARa inactivation antagonizes leukemogenesis in transgenc mouse models of APL. The American Society of Hematology, 2003 Annual Meeting. San Diego, CA. December 6-9, 2003. |
|  | . **P. P. Scaglioni**, R. Bernardi, T. Maeda, L. F. Cai, P. P. Pandolfi. The PML tumor suppressor protein is degraded by the ubiquitin/proteasome system during cellular transformation. The American Society of Hematology, 2003 Annual Meeting. San Diego, CA. December 6-9, 2003 |
|  | **P.P. Scaglioni**, T. Yung, L.F. Cai, P.P. Pandolfi. Activation of the p38 MAPK pathway results in ubiquitin-proteasome degradation of the PML tumor suppressor protein. The American Society of Hematology, 2004 Annual Meeting. San Diego, CA. December 4-7, 2004. |
|  | **P.P. Scaglioni,** T.M Yung, L.F. Cai, H Erdjument-Bromage, A.J. Kaufman, B. Singh, J. Teruya-Feldstein, P. Tempst, P.P. Pandolfi. A CK2-Dependent Mechanism for PML degradation in non-small cell lung cancer. Mechanisms and Models of Cancer. Cold Spring Harbor Laboratory. NY. August 16-20, 2006. |
|  | S. Choi, G. Konstantinidou, R. Bernardi, T. M. Yung, P.P. pandolfi, **P.P. Scaglioni**. Oncogenic Ras triggers selective induction of PML translation during replicative senescence. Mechanisms and Models of Cancer. Cold Spring Harbor. August 13-17 2008. |
|  | G. Konstantinidou, E. Bey, K. Schuster, A. Rabellino, M. Maira, A. Gazdar, D. Boothman and **P.P. Scaglioni**. Dual PI3K/mTOR blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations. Mechanisms and Models of Cancer. La Jolla, CA. August 12-16, 2009 |
|  | K. Schuster, G. Konstantinidou and **P.P. Scaglioni**. Dual inhibition of PI3K and mTOR in chronic myeloid leukema (CML). Mechanisms and Models of Cancer. La Jolla, CA. August 12-16, 2009. |
|  | A. Rabellino, G. Konstantinidou, B. Carter, S.Y. Wu, C.M. Chiang and **P.P. Scaglioni**. The PIAS1 SUMO-E3 ligase regulates tumorigenesis through SUMOylation of the PML tumor suppressor. Mechanisms and Models of Cancer. Cold Spring Harbor. August 17-21, 2010. |
|  | A. Rabellino, G. Konstantinidou, B. Carter, S.Y. Wu, C.M. Chiang and **P.P. Scaglioni**. The PIAS1 SUMO-E3 ligase regulates tumorigenesis through SUMOylation of the PML tumor suppressor. Mechanisms and Models of Cancer. Cold Spring Harbor. August 17-21, 2010 |
|  | A. Rabellino, B. Carter, G. Konstantinidou, S.W. Wu, A. Rimessi, L.A. Beyers, J.V. Heymach, L. Girard, C.M. Chiang, J. Teruya-Feldstein and P.P. Scaglioni. SUMOylation and tumorigenesis: a novel oncogenic role for the SUMO-Ligase PIAS1. Mechanisms and Models of Cancer.Cold Spring Harbor Laboratories, Cold Spring Harbor, NY. August 14-18 2012. |
|  | A. Rabellino, M. Melegari and P.P. Scaglioni. PIAS1 promotes c-MYC SUMOylation and stabilization, promoting tumorigenesis. Mechanisms and Models of Cancer. Salk Institute, La Jolla, CA. August 7-10 2013. |
|  | J.D. Constanzo, A. Rabellino, G. Konstantinidou, K. Schuster and P.P. Scaglioni. SUMO Ligase PIAS1: An Unexpected Role In Cancer Cell Initiation And Survival. Mechanisms and Models of Cancer. Salk Institute, La Jolla, CA. August 7-10 2013. |
|  | G. Konstantinidou, G. Ramadori, F. Torti, C. Behrens, I. I. Wistuba, A. Heguy, D. Gerber, J. Teruya-Feldstein, P.P. Scaglioni. Identification of Focal Adhesion Kinase (FAK) as a Therapeutic Target in KRAS Mutant Lung Cancer. Mechanisms and Models of Cancer. Salk Institute, La Jolla, CA. August 7-10 2013. |
|  | K. Schuster, N. Venkateswaran, S. Peña-Llopis and P.P. Scaglioni. Loss of the CDKN2AB Tumor Suppressor Locus Promotes Mutant KRAS Lung Tumorigenesis. Mechanisms and Models of Cancer. Salk Institute, La Jolla, CA. August 7-10 2013. |
|  | D.E. Gerber, S.S. Ramalingam, D. Morgensztern, R. Kelly, T.F. Burns, A. Lopez-Chavez, A. Wehbe, D.R. Spigel, R. Sorensen, D. Weaver, J. Horobin, M. Keegan, **P. P. Scaglioni**, D. R. Camidge. A phase 2 study of defactinib (VS-6063), a cancer stem cell inhibitor that acts through inhibition of focal adhesion kinase (FAK), in patients with KRAS-mutant non-small cell lung cancer. 2014 ASCO Annual Meeting. J Clin Oncol 32:5s, 2014 (suppl; abstr TPS8126). |
|  | A. Rabellino, M. Melegari, S.Y. Wu, V.S. Tompkins, S. Janz, J.D. Minna, M. Conacci-Sorell, J. Teruya-Feldstein and **P. P. Scaglioni**. The SUMO E3 ligase PIAS1 is a novel positive regulator of c-MYC driven tumorigenesis. Mechanisms and Models of Cancer. Cold Spring Harbor, NY. August 12-16, 2014. |
|  | M.S. Padanad, G. Konstantinidou, C. Yang, M. Melegari, N. Venkateswaran, K. Batten, K.E. Huffman, J.W. Shay, J.D. Minna, R.J. DeBerardinis and **P. P. Scaglioni**. Acyl-CoA synthetase long-chain family member 3 is required for mutant KRAS driven lung cancer. Mechanisms and Models of Cancer. Cold Spring Harbor, NY. August 12-16, 2014. |
|  | G. Konstantinidou, M.S. Padanad, C. Yang, M. Melegari, N. Venkateswaran, K. Batten, K.E. Huffman, J.W. Shay, J.D. Minna, R.J. DeBerardinis and **P.P. Scaglioni**. Acyl-CoA synthetase long-chain family member 3 (ACSL3) is required for mutant KRAS driven lung cancer. Lung Cancer SPORE Meeting, Rockville, MD, July 25-26, 2014. |
|  | M.S. Padanad, G. Konstantinidou, C.Yang, M. Melegari, N. Venkateswaran, K. Batten, K.E. Huffman, J.W. Shay, J.D. Minna, R.J. DeBerardinis and **P.P. Scaglioni**. Acyl-CoA synthetase long-chain family member 3 is required for mutant KRAS driven lung cancer. Keystone Symposium: Integrating Metabolism and Tumor Biology. Vancouver, Canada. January 13-18, 2015. |
|  | M.S. Padanad, G. Konstantinidou, C. Yang, M. Melegari, N. Venkateswaran, K. Batten, K.E. Huffman, J.W. Shay, J.D. Minna, R.J. DeBerardinis and **P.P. Scaglioni.** Acyl-CoA synthetase long-chain family member 3 is required for mutant KRAS driven lung cancer. Trainee Symposium on Cancer Research in Texas, BioScience Research Collaborative (BRC), Houston, Texas, USA. January 30, 2015. |
|  | M.S. Padanad, G. Konstantinidou, C. Yang, M. Melegari, N. Venkateswaran, K. Batten, K.E. Huffman, J.W. Shay, J.D. Minna, R.J. DeBerardinis and **P.P. Scaglioni.** Acyl-CoA synthetase long-chain family member 3 is required for mutant KRAS driven lung cancer. International Association for the Study of Lung Cancer (IASLC). The Fairmont Miramar Hotel, Santa Monica, CA. February 18-21, 2015. |
|  | S. Rindhe, N. Venkateswaran, M.S. Padanad, A. Rabellino, M. Melegari and **P.P. Scaglioni.** PML supports KRAS driven lung cancer growth via metabolic reprogramming. AACR Special Conference of Cancer Metabolism. Hyatt Regency Bellevue, Washington, WA, June 7-10, 2015. |
|  | M.S. Padanad, G. Konstantinidou, C. Yang, M. Melegari, N. Venkateswaran, K. Batten, K.E. Huffman, J.W. Shay, J.D. Minna, R.J. DeBerardinis and **P.P. Scaglioni.** Acyl-CoA synthetase long-chain family member 3 is required for mutant KRAS driven lung cancer. AACR Special Conference of Cancer Metabolism. Hyatt Regency Bellevue, Washington, WA, June 7-10, 2015. |
|  | K.J. Tang, J.D. Constanzo, N. Venkateswaran, M. Melegari, J.C. Morales, D.A. Boothman, **Scaglioni P.P**. Pharmacologic inhibition or genetic ablation of Focal adhesion kinase (FAK) is radiosensitizing in mutant KRAS lung cancer. Lung Cancer SPORE Workshop. Rockville, MD. June 15-16, 2015. |
|  | J.D. Constanzo, M. Deng, S. Rindhe, K.J. Tang, C.C. Zhang and **P.P. Scaglioni** Pias1 Deficiency Induces Failure of Yolk Sac Erythrogenesis and Cardiovascular Development in the Mouse Embryo. The 10th Symposium Mechanisms and Models of Cancer. The Salk Institute, La Jolla, CA. August 5-8, 2015. |
|  | J.D. Constanzo,K.J. Tang, S. Rindhe, N. Venkateswaran, M. Melegari and **P.P. Scaglioni.** *FAK and PIAS1* Genes Promote the Survival and Progression of Aggressive Metastatic Lung Cancer by Engaging DNA Repair Networks and Mitochondria Metabolism. The 10th Symposium Mechanisms and Models of Cancer. The Salk Institute, La Jolla, CA. August 5-8, 2015. |
|  | D.E. Gerber, D.R. Camidge, D. Morgensztern, J. Cetnar, R.J. Kelly, S.S. Ramalingam, D.R. Spigel, W. Jeong, **P.P. Scaglioni**, M. Li, M. Keegan, J.C. Horobin, T.F. Burns. Phase II study of Defactinib, VS-6063, a focal adhesion kinase (FAK) inhibitor, in patients with KRAS mutant non-small cell lung cancer (NSCLC). 16th World Conference on Lung Cancer. Denver, CO. September, 6-9, 2015 |
|  | C. Bartolacci, M. Padanad, C. Andreani, M. Melegari, S. Rindhe, G. Kemble, A. Frankel, J. McDonald, **P.P. Scaglioni**. Fatty acid synthase is a therapeutic target in mutant KRAS lung cancer. Lung Cancer SPORE Workshop. Yale West Campus, Orange, CT. June 22, 2017. |
|  | C. Andreani, A. Rabellino, C. Bartolacci, S. Berto, M. Melegari, **P.P. Scaglioni.** PIAS1 SUMO E3-ligase: a vulnerability of MYC-driven B-cell lymphoma. 11th Annual Symposium Mechanisms and Models of Cancer. Salk Institute, La Jolla, CA. August 1-4, 2017 |
|  | C. Bartolacci, C. Andreani, M. Padanad, G. Vias Do Vale, M. Melegari, J. McDonald, and **P.P. Scaglioni.** Characterization of the lipid profile of mutant KRAS lung cancer designs FASN as a novel therapeutic target. 11th Annual Symposium Mechanisms and Models of Cancer. Salk Institute, La Jolla, CA. August 1-4, 2017. |
|  | C. Bartolacci, C. Andreani, G. Vias Do Vale, M. Melegari, D. Baluya, G. Kemble, D. Gerber, J. Minna, J. McDonald and **P.P. Scaglioni**. FASN as a novel Therapeutic Target in Mutant KRAS Lung Cancer. Mechanisms and Models of Cancer. Cold Spring Harbor, NY. August 14-18, 2018. |
|  | C. Andreani, C. Bartolacci, G. Vias Do Vale, M. Melegari, J. McDonald, G. Kemble, J. Minna, E. Martinez and **Scaglioni PP.** KDM6B demethylase promotes acquired resistance to FASNi in mutant KRAS NSCLC cells. Mechanisms and Models of Cancer. Cold Spring Harbor, NY. August 14-18, 2018 |
|  | C. Bartolacci, C. Andreani, G. Vias Do Vale, M. Melegari, D. Baluya, G. Kemble, J. McDonald and **P.P. Scaglioni**. KRAS hijacks fatty acid metabolism in lung Cancer. Regulation and Function of Small GTPases Conference. St. Bonaventure University. Olean, NY. June 23-28, 2019. |
|  | C. Andreani, C. Bartolacci, G. Vias Do Vale, M. Melegari, J. McDonald, G. Kemble, J. Minna, E. Martinez and **Scaglioni PP.** Epigenetic mechanisms of acquired resistance to FASN inhibition in mutant KRAS lung cancer. St. Bonaventure University. Olean, NY. June 23-28, 2019. |
|  | C. Bartolacci, C. Andreani, G. Vias Do Vale, M. Melegari, D. Baluya, G. Kemble, J. McDonald and **P.P. Scaglioni**. FASN imposes a targetable metabolic dependency on mutant KRAS lung cancer. Mechanisms and Models of Cancer. The Salk Institute, La Jolla, CA. July 30-August 2, 2019. |